BASEL, SWITZERLAND – The recent EU Variations Regulation that took effect in January is expected to simplify and future-proof the process for implementing manufacturing changes for medicinal products, ...
Dublin, April 13, 2026 (GLOBE NEWSWIRE)-- The "Variations to Marketing Authorisations (June 2nd - June 3rd, 2026)" training has been added to ResearchAndMarkets.com's offering. This course will be ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the European Medicines Agency or EMA has validated a Type II Variation Marketing Authorization ...
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to ...
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) ...
Sept 20 (Reuters) - Bristol-Myers Squibb Co : * European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer Sign ...
(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities lie in optimizing regulatory procedures for EU variation submissions, enhancing understanding of Module 3 impacts, and leveraging industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results